Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
70.00    0.00 (0.00%)
Bid:
69.00
Ask:
71.00
Spread: 2.00 (2.899%)
Market Cap: £318.58m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Directorate Appointment

9 Nov 2007 16:59

Avacta Group plc Board Appointment

Avacta Group plc ("Avacta" or the "Company"), which develops detection and analysis technology aimed at the biopharmaceutical, defence & security and clinical diagnostics markets, is pleased to announce the appointment of Russell Hodgetts to the Board of Directors, with effect from 10 July 2007.

Russell Winston Hodgetts, 36, has been Chief Operating Officer of Avacta since October 2005, and has a wealth of experience in strategic business development and group operations. Prior to joining Avacta he worked for Techtran Group Limited where he helped guide the commercialization and business development of companies created from University of Leeds research and intellectual property.

He currently oversees the development of the analytical services division of the Company in addition to being responsible for group operations.

Russell Hodgetts is the beneficial owner of 9,847,912 ordinary shares of 0.1p each in the capital of the Company ("Ordinary Shares"), representing approximately 1.27 per cent. of the issued share capital of the Company and 1,804,568 options to acquire Ordinary Shares at an exercise price of 2.25p per share.

He is also a director of Avacta Analytical Limited.

Russell Hodgetts was named Russell Beckett until family circumstances led to his name being changed when aged 11.

There are no other disclosures required by paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Professor Alastair Smith, Chief Executive, Avacta Group plc, commented:

"Russell has been an integral part of the development of Avacta over the past two years and his focus on continued growth has been central to the success of Avacta Analytical Ltd. We are pleased to welcome him to the Board and will continue to draw on his knowledge and drive to ensure that Avacta maintains its current path of development and innovation."

9 November 2007EnquiriesAvacta Group plc Tel: 0870 835 4367 Alastair Smith, Chief Executive WH Ireland Limited Tel: 0161 832 2174 David Youngman/Robin Gwyn BankOra Limited Tel: 020 7562 4713 Henry Turcan/Michael Brennan Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk

AVACTA GROUP PLC
Date   Source Headline
8th Apr 20221:57 pmRNSIssue of Equity and Total Voting Rights
8th Apr 20227:00 amRNSAffyXell partners with Biocytogen and KNTSC
7th Apr 20224:31 pmRNSIssue of Equity and Total Voting Rights
6th Apr 20227:00 amRNSPreliminary Results
30th Mar 20224:41 pmRNSSecond Price Monitoring Extn
30th Mar 20224:35 pmRNSPrice Monitoring Extension
30th Mar 20227:00 amRNSNotice of Results and Investor Presentation
29th Mar 20227:00 amRNSAVA6000 data poster presentation at AACR
21st Mar 20227:00 amRNSDirectorate Change
16th Mar 20227:00 amRNSVimian acquires Avacta’s Animal Health Division
14th Feb 20224:41 pmRNSSecond Price Monitoring Extn
14th Feb 20224:36 pmRNSPrice Monitoring Extension
7th Feb 20224:36 pmRNSPrice Monitoring Extension
3rd Feb 20225:26 pmRNSIssue of Equity and Total Voting Rights
3rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20224:35 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSDose escalation in the phase I trial of AVA6000
31st Jan 20224:41 pmRNSSecond Price Monitoring Extn
31st Jan 20224:36 pmRNSPrice Monitoring Extension
18th Jan 20227:00 amRNSSecond pre|CISION Pro-drug Candidate Selected
12th Jan 20222:05 pmRNSSecond Price Monitoring Extn
12th Jan 20222:00 pmRNSPrice Monitoring Extension
10th Jan 20227:00 amRNSUpdate on AffiDX and detection of Omicron variant
4th Jan 202211:06 amRNSSecond Price Monitoring Extn
4th Jan 202211:01 amRNSPrice Monitoring Extension
22nd Dec 20214:26 pmRNSIssue of Equity and Total Voting Rights
22nd Dec 202111:05 amRNSSecond Price Monitoring Extn
22nd Dec 202111:00 amRNSPrice Monitoring Extension
22nd Dec 20217:00 amRNSAffiDX Receives CE Mark for Consumer Self-Testing
16th Dec 20217:00 amRNSIssue of Equity and Total Voting Rights
15th Dec 20217:00 amRNSAffiDx® lateral flow test detects Omicron variant
15th Dec 20217:00 amRNSChange of auditor
29th Nov 20217:00 amRNSFDA Approval of IND Application for AVA6000
18th Nov 20214:41 pmRNSSecond Price Monitoring Extn
18th Nov 20214:36 pmRNSPrice Monitoring Extension
2nd Nov 20217:00 amRNSUpdate on UK Availability of AffiDX Test
14th Oct 20214:36 pmRNSPrice Monitoring Extension
14th Oct 202112:36 pmRNSIssue of Equity and Total Voting Rights
30th Sep 20217:00 amRNSInterim Results for the Period Ended 30 June 2021
29th Sep 20217:00 amRNSDevelopment Milestone in LG Chem Partnership
9th Sep 20217:00 amRNSNotice of Results
2nd Sep 20217:00 amRNSAppointment of Chief Scientific Officer
25th Aug 20214:40 pmRNSSecond Price Monitoring Extn
25th Aug 20214:35 pmRNSPrice Monitoring Extension
18th Aug 20217:00 amRNSDirectorate Change
11th Aug 20217:00 amRNSFirst Patient Dosed in AVA6000 Phase 1 Trial
4th Aug 20217:00 amRNSUpdate on AffiDX Lateral Flow Test
14th Jul 20217:00 amRNSDiagnostics achieves ISO 13485 Certification
12th Jul 20214:41 pmRNSSecond Price Monitoring Extn
12th Jul 20214:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.